JP2014512183A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014512183A5 JP2014512183A5 JP2014503979A JP2014503979A JP2014512183A5 JP 2014512183 A5 JP2014512183 A5 JP 2014512183A5 JP 2014503979 A JP2014503979 A JP 2014503979A JP 2014503979 A JP2014503979 A JP 2014503979A JP 2014512183 A5 JP2014512183 A5 JP 2014512183A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cell
- extracellular domain
- individual
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 20
- 230000003834 intracellular effect Effects 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 6
- 210000000987 immune system Anatomy 0.000 claims 6
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 208000000277 Splenic Neoplasms Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 3
- 206010057644 Testis cancer Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 201000010175 gallbladder cancer Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 201000005787 hematologic cancer Diseases 0.000 claims 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 206010038038 rectal cancer Diseases 0.000 claims 3
- 201000001275 rectum cancer Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 201000002471 spleen cancer Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 201000003120 testicular cancer Diseases 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 102000003816 Interleukin-13 Human genes 0.000 claims 2
- 108090000176 Interleukin-13 Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000003675 cytokine receptors Human genes 0.000 claims 2
- 108010057085 cytokine receptors Proteins 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 101000972282 Homo sapiens Mucin-5AC Proteins 0.000 claims 1
- 101000972278 Homo sapiens Mucin-6 Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 1
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- -1 MAGEA Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 102100022496 Mucin-5AC Human genes 0.000 claims 1
- 102100022493 Mucin-6 Human genes 0.000 claims 1
- 108060006580 PRAME Proteins 0.000 claims 1
- 102000036673 PRAME Human genes 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 1
- 102100037686 Protein SSX2 Human genes 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 108010017842 Telomerase Proteins 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 210000004986 primary T-cell Anatomy 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161473457P | 2011-04-08 | 2011-04-08 | |
| US61/473,457 | 2011-04-08 | ||
| PCT/US2012/032322 WO2012138858A1 (en) | 2011-04-08 | 2012-04-05 | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016246100A Division JP6297129B2 (ja) | 2011-04-08 | 2016-12-20 | キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014512183A JP2014512183A (ja) | 2014-05-22 |
| JP2014512183A5 true JP2014512183A5 (OSRAM) | 2015-04-09 |
| JP6066991B2 JP6066991B2 (ja) | 2017-01-25 |
Family
ID=46969548
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014503979A Expired - Fee Related JP6066991B2 (ja) | 2011-04-08 | 2012-04-05 | キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法 |
| JP2016246100A Active JP6297129B2 (ja) | 2011-04-08 | 2016-12-20 | キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法 |
| JP2018027460A Pending JP2018108091A (ja) | 2011-04-08 | 2018-02-20 | キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016246100A Active JP6297129B2 (ja) | 2011-04-08 | 2016-12-20 | キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法 |
| JP2018027460A Pending JP2018108091A (ja) | 2011-04-08 | 2018-02-20 | キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10548921B2 (OSRAM) |
| EP (2) | EP3305890B1 (OSRAM) |
| JP (3) | JP6066991B2 (OSRAM) |
| CN (2) | CN103582699B (OSRAM) |
| AU (3) | AU2012240135B2 (OSRAM) |
| CA (1) | CA2832569A1 (OSRAM) |
| DK (1) | DK2694640T3 (OSRAM) |
| ES (1) | ES2649967T3 (OSRAM) |
| MX (2) | MX380522B (OSRAM) |
| NO (1) | NO2724929T3 (OSRAM) |
| NZ (3) | NZ723731A (OSRAM) |
| WO (1) | WO2012138858A1 (OSRAM) |
Families Citing this family (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
| US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
| US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP2015519080A (ja) * | 2012-06-11 | 2015-07-09 | ウィルソン ウォルフ マニュファクチャリング コーポレイションＷｉｌｓｏｎ Ｗｏｌｆ Ｍａｎｕｆａｃｔｕｒｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ | 養子細胞療法のための改良型細胞培養方法 |
| JP6445434B2 (ja) | 2012-08-09 | 2018-12-26 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | スーパーカインおよびシンセカイン：新規かつ増強されたシグナル伝達活性を有する再利用されるサイトカイン |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| EP2953475B1 (en) * | 2013-02-06 | 2019-07-03 | Celgene Corporation | Modified t lymphocytes having improved specificity |
| WO2014130635A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| EP2958943B1 (en) | 2013-02-20 | 2019-09-11 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| US9745368B2 (en) | 2013-03-15 | 2017-08-29 | The Trustees Of The University Of Pennsylvania | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| HK1220205A1 (zh) | 2013-03-15 | 2017-04-28 | Celgene Corporation | 修饰的t淋巴细胞 |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| JP6578271B2 (ja) * | 2013-04-17 | 2019-09-18 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 免疫抑制ＴＧＦ−βシグナルコンバーター |
| JP2016526536A (ja) * | 2013-06-14 | 2016-09-05 | ザ ユニバーシティ オブ ヒューストン システム | 修飾されたキメラ抗原受容体による腫瘍新生血管構造の標的化 |
| WO2015010096A1 (en) | 2013-07-18 | 2015-01-22 | Baylor College Of Medicine | Method of enhancing potency of immune cells |
| WO2015090230A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| JP6793902B2 (ja) | 2013-12-20 | 2020-12-02 | ノバルティス アーゲー | 調節可能キメラ抗原受容体 |
| ES2963718T3 (es) | 2014-01-21 | 2024-04-01 | Novartis Ag | Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras |
| PL3888674T3 (pl) | 2014-04-07 | 2024-09-23 | Novartis Ag | Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19 |
| CN106459924A (zh) * | 2014-04-23 | 2017-02-22 | 得克萨斯州大学系统董事会 | 用于疗法中的嵌合抗原受体(car)及其制备方法 |
| BR112017000939A2 (pt) | 2014-07-21 | 2017-11-14 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico de cll-1 |
| EP3722316A1 (en) | 2014-07-21 | 2020-10-14 | Novartis AG | Treatment of cancer using a cd33 chimeric antigen receptor |
| JP7054622B2 (ja) | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置 |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| JP6631865B2 (ja) * | 2014-08-11 | 2020-01-15 | 日本化薬株式会社 | ＴＧＦβ阻害機能を持つキメラタンパク質 |
| ES2791248T3 (es) | 2014-08-19 | 2020-11-03 | Novartis Ag | Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer |
| US10577417B2 (en) | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| CN114107424A (zh) | 2014-10-08 | 2022-03-01 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
| MA41538A (fr) * | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
| IL253149B2 (en) | 2014-12-29 | 2023-11-01 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| CA2975147C (en) | 2015-01-31 | 2025-06-10 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS OF ADMINISTRATION OF THERAPEUTIC MOLECULES TO T CELLS |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| IL284985B2 (en) | 2015-02-18 | 2023-03-01 | Enlivex Therapeutics R& D Ltd | Combined immunotherapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| MY196588A (en) | 2015-03-05 | 2023-04-19 | Hutchinson Fred Cancer Res | Immunomodulatory Fusion Proteins and uses Thereof |
| CA2980039A1 (en) * | 2015-03-20 | 2016-09-29 | Children's National Medical Center | Generating virus or other antigen-specific t cells from a naive t cell population |
| JP6961490B2 (ja) | 2015-04-08 | 2021-11-05 | ノバルティス アーゲー | Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法 |
| WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| CA2982452A1 (en) | 2015-04-21 | 2016-10-27 | Enlivex Therapeutics Ltd. | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| US12128069B2 (en) | 2015-04-23 | 2024-10-29 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| CN104910279B (zh) * | 2015-06-05 | 2019-02-22 | 重庆精准生物技术有限公司 | 靶向癌胚抗原的嵌合抗原受体、慢病毒表达载体及其制备方法和应用 |
| AR105433A1 (es) | 2015-07-21 | 2017-10-04 | Novartis Ag | Métodos para mejorar la eficacia y expansión de las células inmunes |
| EP3331913A1 (en) | 2015-08-07 | 2018-06-13 | Novartis AG | Treatment of cancer using chimeric cd3 receptor proteins |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| WO2017040930A2 (en) | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| HK1257295A1 (zh) | 2015-12-04 | 2019-10-18 | Novartis Ag | 用於免疫肿瘤学的组合物和方法 |
| EP3393504B1 (en) | 2015-12-22 | 2025-09-24 | Novartis AG | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
| US11730761B2 (en) | 2016-02-18 | 2023-08-22 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| CU24649B1 (es) * | 2016-03-19 | 2023-02-13 | Exuma Biotech Corp | Retrovirus recombinantes incompetentes de replicación para la transducción de linfocitos y expansión regulada de los mismos |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| KR102608966B1 (ko) * | 2016-08-26 | 2023-12-04 | 베이롤 칼리지 오브 메드신 | 세포 치료요법을 위한 항상성 활성 사이토킨 수용체 |
| WO2018067992A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
| EP4092049A1 (en) | 2016-10-20 | 2022-11-23 | Celgene Corporation | Cereblon-based heterodimerizable chimeric antigen receptors |
| IL309526B2 (en) | 2016-11-17 | 2025-02-01 | 2Seventy Bio Inc | TGFBeta signal converter |
| US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
| GB201702617D0 (en) * | 2017-02-17 | 2017-04-05 | Autolus Ltd | Receptor |
| IL268739B2 (en) * | 2017-03-03 | 2024-11-01 | F1 Oncology Inc | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
| JP2020511136A (ja) | 2017-03-17 | 2020-04-16 | フレッド ハッチンソン キャンサー リサーチ センター | 免疫調節性融合タンパク質およびその使用 |
| EP3601561A2 (en) | 2017-03-22 | 2020-02-05 | Novartis AG | Compositions and methods for immunooncology |
| EP4317422A3 (en) | 2017-04-13 | 2024-05-01 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| WO2019073299A1 (en) | 2017-10-10 | 2019-04-18 | Medicenna Therapeutics, Inc. | IL-4 FUSION FORMULATIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS |
| KR20200086278A (ko) | 2017-10-18 | 2020-07-16 | 노파르티스 아게 | 선택적 단백질 분해를 위한 조성물 및 방법 |
| CN118420783A (zh) * | 2017-12-06 | 2024-08-02 | 恺兴生命科技(上海)有限公司 | 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用 |
| IL276831B2 (en) * | 2018-03-02 | 2025-04-01 | Allogene Therapeutics Inc | Chimeric inducible cytokine receptors |
| US10780120B2 (en) | 2018-03-06 | 2020-09-22 | The Trustees Of The University Of Pennsylvania | Prostate-specific membrane antigen cars and methods of use thereof |
| WO2019239213A2 (en) | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
| US20210214410A1 (en) * | 2018-06-01 | 2021-07-15 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| TWI890660B (zh) | 2018-06-13 | 2025-07-21 | 瑞士商諾華公司 | Bcma 嵌合抗原受體及其用途 |
| CN110615843B (zh) | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
| US10993967B2 (en) | 2018-10-17 | 2021-05-04 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| WO2020097582A1 (en) * | 2018-11-08 | 2020-05-14 | WUGEN, Inc. | Compositions and methods for treatment of cancer |
| CN116479022A (zh) * | 2018-12-12 | 2023-07-25 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
| US12043655B2 (en) | 2019-03-01 | 2024-07-23 | Allogene Therapeutics, Inc. | Constitutively active chimeric cytokine receptors |
| CN113518785A (zh) * | 2019-03-01 | 2021-10-19 | 艾洛基治疗公司 | 携带pd-1胞外域的嵌合细胞因子受体 |
| US12485180B2 (en) | 2019-08-30 | 2025-12-02 | Yale University | Compositions and methods for delivery of nucleic acids to cells |
| KR102275668B1 (ko) * | 2019-09-26 | 2021-07-12 | 충북대학교 산학협력단 | 면역신호의 변환이 가능한 키메릭 사이토카인 수용체, 이를 발현하는 면역세포 및 이의 항암 용도 |
| AR120566A1 (es) | 2019-11-26 | 2022-02-23 | Novartis Ag | Receptores de antígeno quiméricos y sus usos |
| BR112022009679A2 (pt) | 2019-11-26 | 2022-08-09 | Novartis Ag | Receptores de antígeno quimérico cd19 e cd22 e usos dos mesmos |
| EP4110805A1 (en) | 2020-02-24 | 2023-01-04 | Allogene Therapeutics, Inc. | Bcma car-t cells with enhanced activities |
| GB2609103A (en) | 2020-02-25 | 2023-01-25 | Quell Therapeutics Ltd | Chimeric receptors for use in engineered cells |
| KR20230079367A (ko) | 2020-08-31 | 2023-06-07 | 예일 유니버시티 | 핵산을 세포에 전달하기 위한 조성물 및 방법 |
| IL316032A (en) | 2022-04-08 | 2024-11-01 | Regeneron Pharma | Multicomponent receptor and signaling complexes |
| JP2025540052A (ja) | 2022-12-01 | 2025-12-11 | イェール ユニバーシティー | 細胞内ペイロード送達用刺激応答性トレースレス操作プラットフォーム |
| CN120225568A (zh) * | 2022-12-27 | 2025-06-27 | 广州瑞风生物科技有限公司 | 一种融合蛋白及其应用 |
| TW202436337A (zh) | 2023-01-23 | 2024-09-16 | 漢諾威醫學院 | 嵌合抗原受體 |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| WO2024165859A1 (en) | 2023-02-07 | 2024-08-15 | Quell Therapeutics Limited | Culture method for treg cells |
| WO2024175805A1 (en) | 2023-02-24 | 2024-08-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| CN116284449B (zh) * | 2023-02-27 | 2024-11-19 | 深圳市先康达生命科学有限公司 | 增强型TGF-βR嵌合受体及其应用 |
| US12257304B2 (en) | 2023-03-03 | 2025-03-25 | Arsenal Biosciences, Inc. | Systems targeting PSMA and CA9 |
| WO2024194605A1 (en) | 2023-03-17 | 2024-09-26 | Quell Therapeutics Limited | Treg therapy |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024194355A1 (en) | 2023-03-20 | 2024-09-26 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024193687A1 (en) * | 2023-03-23 | 2024-09-26 | Nanjing Legend Biotech Co., Ltd. | Inverted cytokine receptors and methods of use thereof |
| WO2024211900A1 (en) * | 2023-04-06 | 2024-10-10 | Memorial Sloan-Kettering Cancer Center | Il-10 receptor antibodies and methods of use thereof |
| CN116496417B (zh) * | 2023-06-27 | 2023-10-10 | 北京市肿瘤防治研究所 | 含有膜型il7的融合蛋白及t细胞 |
| WO2025016399A1 (en) * | 2023-07-17 | 2025-01-23 | Nanjing Legend Biotech Co., Ltd. | Fusion proteins and methods of use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747292A (en) * | 1993-04-06 | 1998-05-05 | Fred Hutchinson Cancer Research Center | Chimeric cytokine receptors in lymphocytes |
| ATE476496T1 (de) * | 1996-03-04 | 2010-08-15 | Calyx Bio Ventures Inc | Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten |
| US6130087A (en) * | 1996-10-07 | 2000-10-10 | Fordham University | Methods for generating cytotoxic T cells in vitro |
| US20020114812A1 (en) | 2001-01-12 | 2002-08-22 | Riichiro Abe | Methods and compositions for modulating regulation of the cytotoxic lymphocyte response by macrophage migration inhibitory factor |
| US20090257994A1 (en) * | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| EP1392818A4 (en) * | 2001-04-30 | 2005-01-05 | Hope City | FOR THE TREATMENT OF CANCER DISEASES IN HUMAN CERTAIN IMMUNE RECEPTOR |
| US7235392B2 (en) | 2001-12-07 | 2007-06-26 | The Ohio State University Research Foundation | Apoptotic EBV-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder |
| US20040138187A1 (en) * | 2002-08-28 | 2004-07-15 | Reading Christopher L. | Therapeutic treatment methods |
| WO2004042025A2 (en) | 2002-11-01 | 2004-05-21 | Cell Genesys, Inc. | Cell-specific adenovirus vector comprising ebv-specific promoter |
| JP2004315381A (ja) * | 2003-04-11 | 2004-11-11 | Japan Science & Technology Agency | ナチュラルキラーＴ細胞のインターロイキン１８による刺激を利用した免疫疾患治療薬剤および治療キット、並びにＩｇＥ産生の制御方法 |
| US7435592B2 (en) * | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| DE602004031341D1 (de) * | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
| WO2007002905A1 (en) * | 2005-06-29 | 2007-01-04 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
| GB0917090D0 (en) | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| CA2934436A1 (en) | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
-
2012
- 2012-04-05 ES ES12767723.5T patent/ES2649967T3/es active Active
- 2012-04-05 MX MX2017005885A patent/MX380522B/es unknown
- 2012-04-05 MX MX2013011742A patent/MX347656B/es active IP Right Grant
- 2012-04-05 NZ NZ723731A patent/NZ723731A/en not_active IP Right Cessation
- 2012-04-05 NZ NZ710810A patent/NZ710810A/en not_active IP Right Cessation
- 2012-04-05 EP EP17190649.8A patent/EP3305890B1/en active Active
- 2012-04-05 WO PCT/US2012/032322 patent/WO2012138858A1/en not_active Ceased
- 2012-04-05 US US14/110,582 patent/US10548921B2/en active Active
- 2012-04-05 CN CN201280024856.1A patent/CN103582699B/zh active Active
- 2012-04-05 EP EP12767723.5A patent/EP2694640B1/en active Active
- 2012-04-05 CA CA2832569A patent/CA2832569A1/en active Pending
- 2012-04-05 CN CN201710136120.8A patent/CN107164330A/zh active Pending
- 2012-04-05 AU AU2012240135A patent/AU2012240135B2/en not_active Ceased
- 2012-04-05 NZ NZ616405A patent/NZ616405A/en not_active IP Right Cessation
- 2012-04-05 DK DK12767723.5T patent/DK2694640T3/da active
- 2012-04-05 JP JP2014503979A patent/JP6066991B2/ja not_active Expired - Fee Related
-
2013
- 2013-08-08 NO NO13003957A patent/NO2724929T3/no unknown
-
2016
- 2016-11-01 AU AU2016253549A patent/AU2016253549B2/en not_active Ceased
- 2016-12-20 JP JP2016246100A patent/JP6297129B2/ja active Active
-
2018
- 2018-02-20 JP JP2018027460A patent/JP2018108091A/ja active Pending
- 2018-07-04 AU AU2018204850A patent/AU2018204850B2/en not_active Ceased
-
2020
- 2020-01-15 US US16/743,968 patent/US11717538B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014512183A5 (OSRAM) | ||
| JP7527049B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| JP6888225B2 (ja) | 改善された特異性を有する改変型ｔリンパ球 | |
| Houot et al. | T-cell–based immunotherapy: adoptive cell transfer and checkpoint inhibition | |
| Kershaw et al. | Gene-engineered T cells for cancer therapy | |
| Gill et al. | Chimeric antigen receptor T cell therapy: 25 years in the making | |
| Dar et al. | Insights into the relationship between toll like receptors and gamma delta T cell responses | |
| JP2017513470A5 (OSRAM) | ||
| JP2018522567A5 (OSRAM) | ||
| ES2837628T3 (es) | Linfocitos T modificados | |
| RU2016143388A (ru) | Экспрессия трансгенов, регулируемая лекарственным средством | |
| JP2017515464A5 (OSRAM) | ||
| SI2856876T1 (en) | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes | |
| Zhang et al. | Genetic engineering with T cell receptors | |
| DeRenzo et al. | The Landscape of CAR T cells beyond ALL for Pediatric Solid Tumors | |
| WO2019210293A1 (en) | Car t cells with one or more interleukins | |
| US20250163128A1 (en) | T cell expressing an fc gamma receptor and methods of use thereof | |
| JP2018531016A5 (OSRAM) | ||
| Prinzing et al. | CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing? | |
| Pedrazzoli et al. | Is adoptive T-cell therapy for solid tumors coming of age? | |
| Hanagiri et al. | Retracted: Antitumor activity of human γδ T cells transducted with CD 8 and with T‐cell receptors of tumor‐specific cytotoxic T lymphocytes | |
| EP4130028A1 (en) | Engineered tcr complex and methods of using same | |
| JPWO2020163634A5 (OSRAM) | ||
| US20250066447A1 (en) | Engineered tcr complex and methods of using game | |
| JP2018522594A5 (OSRAM) |